Merck & Company (6MK) Price & Analysis
6MK Stock Chart & Stats
- Day’s Range
- EUR 131.66 - EUR 135.16
- 52-Week Range
- EUR 71.40 - EUR 136.44
- Previous Close
- EUR 132.32
- Volume
- 294
- Average Volume (3M)
- 1,191
- Market Cap
- EUR 329.20B
- Enterprise Value
- EUR 364.17B
- Total Cash (Recent Filing)
- EUR 7.14B
- Total Debt (Recent Filing)
- EUR 53.91B
- Price to Earnings (P/E)
- 152.6
- Beta
- 0.47
- Next Earnings
- Feb 02, 2027
- EPS Estimate
- 1.6
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.18%
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Robust free cash flow gives Merck internal funding for dividends, share repurchases, debt service, and business development. Healthy conversion from earnings provides resilience while the company invests in launches and its pipeline, although annual cash flow has shown some volatility.
Diversified Growth Portfolio
Growth across oncology, vaccines, animal health, and newer products reduces dependence on any single therapeutic asset. Strong expansion from WELIREG and WINREVAIR, alongside animal-health growth, creates multiple commercial contributors that can support revenue durability.
Pipeline Strength
Positive Phase 3 results for sac-TMT provide evidence that Merck’s late-stage pipeline can add future oncology revenue beyond KEYTRUDA. Meaningful survival benefits and potential regulatory progress strengthen the company’s ability to replenish growth as older products mature.
Bears Say
Upcoming Loss-of-Exclusivity Headwinds
Generic competition and loss of exclusivity affecting BRIDION, Januvia, and Adempas create a visible medium-term revenue drag. Management expects more than $2 billion of pressure in 2027, requiring new launches and pipeline assets to offset erosion from established products.
Lower Profitability And Higher Leverage
The sharp TTM decline in net income and net margin reduces earnings predictability and weakens returns on the existing capital base. Higher leverage further limits flexibility if profitability remains pressured, even though Merck still generates substantial cash and retains sizeable assets.
Rising Investment Costs
Higher operating expenses reflect investment in launches and the pipeline, but they can suppress near-term margins before those programs generate meaningful revenue. Continued mid-to-high single-digit expense growth increases execution demands and makes earnings more sensitive to commercial timing.
Merck & Company News
Merck Stock (MRK) Rises 2% on $830 Million Keytruda Sales Beat, Q3 Forecasts, and Higher Full-Year Profit Outlook
Merck & Co ($MRK) shares rose 2.14% in Thursday premarket trading after the drugmaker beat third-quarter Wall Street estimates and raised its full-year adjusted profit forecast. Strong demand for its
6MK FAQ
What was Merck & Company’s price range in the past 12 months?
What is Merck & Company’s market cap?
When is Merck & Company’s upcoming earnings report date?
How were Merck & Company’s earnings last quarter?
Is Merck & Company overvalued?
Does Merck & Company pay dividends?
What is Merck & Company’s EPS estimate?
How many shares outstanding does Merck & Company have?
What happened to Merck & Company’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Merck & Company?
What is the TipRanks Smart Score and how is it calculated?
Merck & Company Stock Smart Score
Company Description
Merck & Company
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis
- Employees
- 74,000
- Website
- www.merck.com
- Address
- 126 East Lincoln Avenue, Rahway, NJ, 07065, US
Merck & Company (6MK) Earnings & Revenues
6MK Company Deck
6MK Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with solid third-quarter revenue growth, raised 2026 guidance, strong performance from KEYTRUDA, WELIREG, WINREVAIR, Gardasil, and animal health, and multiple favorable clinical and regulatory milestones. Management expressed increased confidence in the pipeline and long-term growth beyond the KEYTRUDA loss-of-exclusivity period. Offsetting concerns included 2027 generic and loss-of-exclusivity headwinds, moderating KEYTRUDA growth, lower adult vaccination utilization, modestly lower gross margin, higher operating expenses, the QLEX European injunctions, and withdrawal of the ifinatamab deruxtecan application. Highlights significantly outweighed the lowlights.
View all DE:6MK earnings summaries6MK Net sales Breakdown
- 89.43% Pharmaceutical
- 9.77% Animal Health
- 0.79% Other
6MK Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 4 | 2 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 12 | 0 | 0 |